FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data

Alfred I. Neugut, Aijing Lin, Gabriel T. Raab, Grace Clarke Hillyer, Deborah Keller, Daniel S. O'Neil, Melissa Kate Accordino, Ravi P. Kiran, Jason Wright, Dawn L. Hershman

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

An examination of the demographic and clinical characteristics associated with the use of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) or leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRI) in patients with stage IV colon cancer found that FOLFOX is prescribed much more frequently than FOLFIRI as first-line therapy, especially in those who were female and those with fewer comorbidities. FOLFOX use has been increasing recently.

Original languageEnglish (US)
Pages (from-to)133-140
Number of pages8
JournalClinical colorectal cancer
Volume18
Issue number2
DOIs
StatePublished - Jun 2019
Externally publishedYes

Keywords

  • Chemotherapy
  • First-line therapy
  • Health outcomes
  • Metastatic cancer
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data'. Together they form a unique fingerprint.

Cite this